CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Clinical trial NCT03328078 · RECRUITING

Trial details

NCT number: NCT03328078
Sponsor: Curis, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Hematologic Malignancy Refractory Hematologic Malignancy Relapsed Primary Central Nervous System Lymphoma Refractory Primary Central Nervous System Lymphoma

Start date: 2017-12-28
Primary completion: 2026-08-01
Enrollment: 152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.